Sacubitril/valsartan is the first agent to be approved in a new class of drugs called angiotensin receptor neprilysin inhibitor (ARNI). The medication is FDA-approved to treat patients with chronic heart failure with reduced ejection fraction (HFrEF) with NYHA class II, III, or IV.
Tell us about your requirement
Price:
Quantity
Select Unit
50
100
200
250
500
1000+
Additional detail
Mobile number
Email
Name
Comapny Name
Phone Number
Email Id
City / State
Confirm Your Requirement
Verification Code
Did not receive yet?
Resend OTP
Youre Done!
We have received your requirements and will reply shortly with the best price.